Ikarian Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ikarian Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,000	Closed	-$4.71M	–	139
2023 Q1	$4.86M	Buy	+50,000	New	+$5.18M	1.1%	31
2022 Q3	–	Sell	-60,000	Closed	-$4.97M	–	117
2022 Q2	$4.97M	Buy	60,000 +10,000	+20%	+$796K	0.91%	35
2022 Q1	$3.86M	Buy	+50,000	New	+$4.18M	0.51%	48

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ikarian Capital's BMRN Position: Q2 2023 in Review

Ikarian Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 50,000 shares — an estimated $4.71M sold.

Ikarian Capital first reported a position in BMRN in Q1 2022 and held it in 3 quarters. The position peaked at $4.97M in Q2 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Ikarian Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 50,000 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $4.71M.
Ikarian Capital first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Ikarian Capital's BioMarin Pharmaceuticals position peaked at $4.97M in Q2 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.